胃癌患者外周血高迁移率族蛋白B-1水平的检测及临床意义

doi:10.3969/j.issn.1673-8640.2013.04.012

检验医学 ›› 2013, Vol. 28 ›› Issue (4): 301-304.DOI: 10.3969/j.issn.1673-8640.2013.04.012

胃癌患者外周血高迁移率族蛋白B-1水平的检测及临床意义

肖锦华

南通大学第三附属医院检验科，江苏无锡 214041

收稿日期:2012-03-26 修回日期:2012-05-22 出版日期:2013-04-30 发布日期:2013-04-05
作者简介:肖锦华，男，1970年生，学士，副主任技师，主要从事肿瘤与内分泌疾病的临床诊断研究。

Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance

Department of Clinical Laboratory，the Third Affiliated Hospital of Nantong University，Jiangsu Wuxi 214041，China

Received:2012-03-26 Revised:2012-05-22 Online:2013-04-30 Published:2013-04-05

摘要/Abstract

摘要： 目的　探讨高迁移率族蛋白B-1（HMGB1）在胃癌患者血清中的变化及临床意义。方法　采用双抗体夹心酶联免疫吸附试验(ELISA)检测101例胃癌患者血清中HMGB1水平，同时用电化学发光法（ECL）测定血清癌胚抗原（CEA）含量，并与31例胃良性病变患者、40名正常对照者比较，数据用中位数（范围）表示。结果　胃癌组患者血清HMGB1和CEA水平分别为15.58（3.05～125.63）ng/mL、11.75（0.85～850.23）ng/mL，胃良性病变组患者血清HMGB1和CEA水平分别为4.46（2.61～12.06）ng/mL、2.75（0.52～11.23）ng/mL，正常对照组血清HMGB1和CEA水平分别为3.24（2.50～5.38）ng/mL、1.23（0.45～4.56）ng/mL，胃癌组患者血清HMGB1和CEA水平显著高于胃良性病变组和正常对照组(P＜0.01）。血清HMGB1水平与胃癌患者肿瘤大小、浸润深度、TNM分期、淋巴结转移密切相关（P均<0.05）。与传统的肿瘤标志物CEA相比，血清HMGB1在早期胃癌患者中显示良好的诊断敏感性（72.2%）和特异性（74.6%）。结论　HMGB1与胃癌的发生、发展有关，检测血清HMGB1含量对于提高胃癌的早期诊断水平、监测病情变化、判断预后具有重要的临床价值。

关键词: 高迁移率族蛋白B-1, 肿瘤标志物, 酶联免疫吸附试验, 胃癌

Abstract: Objective　To investigate the change and clinical significance of serum high mobility group protein box-1 (HMGB1) in patients with gastric cancer. Methods　The serum levels of HMGB1 were determined by enzyme-linked immunosorbent assay (ELISA) in 101 patients with gastric cancer，31 patients with benign gastric diseases and 40 healthy controls. Simultaneously，serum carcinoembryonic antigen(CEA) was determined by electrochemiluminescence (ECL). The results were expressed as median (range). Results　The levels of serum HMGB1 and CEA in patients with gastric cancer were 15.58（3.05-125.63）ng/mL and 11.75（0.85-850.23）ng/mL. The levels of serum HMGB1 and CEA in patients with benign gastric diseases were 4.46（2.61-12.06）ng/mL and 2.75（0.52-11.23）ng/mL. The levels of serum HMGB1 and CEA in healthy controls were 3.24（2.50-5.38）ng/mL and 1.23（0.45- 4.56）ng/mL. The levels of serum HMGB1 and CEA in patients with gastric cancer were significantly higher than those in patients with benign gastric diseases and healthy controls ( P＜0.01）. The levels of serum HMGB1 were significantly associated with tumor size，gastric wall invasion, TNM stage and lymph node metastasis（P＜0.05）. Compared to the traditional tumor marker CEA, the diagnostic sensitivity and specificity of serum HMGB1 were 72.2% and 74.6% for the diagnosis of early gastric cancer. Conclusions　HMGB1 plays a role in the tumorigenesis and development of gastric cancer. The determination of HMGB1 in serum of patients with gastric cancer is helpful for improving early diagnosis, monitoring and predicting the prognosis in gastric cancer.

Key words: High mobility group protein box-1, Tumor marker, Enzyme-linked immunosorbent assay, Gastric cancer

肖锦华，朱华燕，王亚萍，潘宇红，黄璇. 胃癌患者外周血高迁移率族蛋白B-1水平的检测及临床意义[J]. 检验医学, 2013, 28(4): 301-304.

XIAO Jinhua，ZHU Huayan，WANG Yaping，PAN Yuhong，HUANG Xuan. Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance[J]. , 2013, 28(4): 301-304.

参考文献

[1]Hotta K，Oyama T，Akamatsu T，et al. A comparison of outcomes of endoscopic submucosal dissection(ESD) for early gastric neoplasms between high-volume and low-volume centers: multi-center retrospective questionnaire study conducted by the Nagano ESD study group[J]. Intern Med，2010,49(4):253-259.
[2]Tang D，Kang R，Zeh H J 3rd，et al. High-mobility group box 1 and cancer[J]. Biochim Biophys Acta,2010,1799(1-2):131-140.
[3]Yamada S，Yakabe K，Ishii J，et al. New high mobility group box 1 assay system[J]. Clin Chim Acta，2006，372(1-2): 173-178.
[4]Yang H，Wang H，Czura CJ，et al. The cytokine activity of HMGB1 [J]. J Leukoc Biol，2005，78(1): 1-8.
[5]Moriwaka Y，Luo Y，Ohmori H，et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer[J]. Pathobiology，2010,77(1):17-23.
[6]Rauvala H，Rouhiainen A. RAGE as a receptor of HMGB1(amphoterin): roles in health and disease[J]. Curr Mol Med，2007，7(8):725-734.
[7]Bao G，Qiao Q，Zhao H，et al. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas[J]. World J Surg Oncol，2010，8:52.
[8]Chung HW，Lee SG，Kim H，et al. Serum high mobility group box-1(HMGB1) is closely associated with the clinical and pathologic features of gastric cancer[J]. J Transl Med，2009,7:38.
[9]Campana L，Bosurgi L，Rovere-Querini P. HMGB1:a two-headed signal regulating tumor progression and immunity[J]. Curr Opin Immunol，2008,20(5):518-523.
[10]Volz HC，Kaya Z，Katus HA，et al. The role of HMGB1/RAGE in inflammatory cardiomyopathy [J]. Semin Thromb Hemost,2010,36(2):185-194.
[11] Volp K, Brezniceanu ML, B?sser S，et al. Increased expression of high mobility group box 1(HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas [J]. Gut，2006,55(2):234-242.

[1]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[2]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[3]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[4]	肖秀美, 梁超, 刘彩红, 李晓光. 新型冠状病毒中和抗体与特异性抗体检测结果一致性分析[J]. 检验医学, 2023, 38(4): 352-356.
[5]	游延军, 张欢, 向乾银, 曹长春, 王健, 曾红, 魏元敏, 吴斌, 黄敬双, 季纯宇, 代苗, 秦枫. 原发性膜性肾病标志物抗PLA2R抗体检测方法比较[J]. 检验医学, 2023, 38(12): 1153-1156.
[6]	郭霜, 刘红莉, 李娅. EB病毒相关胃癌迁移、侵袭相关miRNA和lncRNA研究进展[J]. 检验医学, 2023, 38(10): 987-996.
[7]	王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881.
[8]	聂甜, 冉子涵, 金磊. 白细胞介素基因多态性与胃癌的相关性研究进展[J]. 检验医学, 2022, 37(9): 882-886.
[9]	冀叶, 袁小笋, 张蕾, 马慧利, 董薇, 李长生, 张敬伟, 任中海, 张怡飞. lncRNA SNHG15在胃癌组织中的表达及临床意义[J]. 检验医学, 2022, 37(5): 409-412.
[10]	梁春芳, 朱康宁, 张琦. 血清miR-21、miR-135a对胃癌患者化疗后复发和转移的预测价值[J]. 检验医学, 2022, 37(5): 417-422.
[11]	黄山, 孙溪若, 吕松琴, 许宝妹, 聂磊, 王义娜, 李晓非. 干式荧光发光法在HIV感染初筛中的应用价值[J]. 检验医学, 2022, 37(2): 174-176.
[12]	徐润灏, 邹琛, 曹芸, 陈风, 刘怡菁, 张舒林, 张洁. 早期非小细胞肺癌患者血清氨基酸检测的临床意义[J]. 检验医学, 2022, 37(12): 1157-1163.
[13]	茆政, 钱增堃, 应斐, 王昭俐, 肖群, 崔凡. E-Cad、G-17、HER-2与胃癌术后复发风险的相关性[J]. 检验医学, 2022, 37(1): 41-46.
[14]	熊仲波, 王蕾, 殷蓓琦, 戴悦, 卫晓青, 卢培. SAA、CRP在胃肠道肿瘤病理分期及转移中的临床价值[J]. 检验医学, 2022, 37(1): 51-55.
[15]	满宪凤, 贺小停, 张莹, 俞卫卫, 王齐, 尹汉维, 王润洁. 硫氧还蛋白还原酶在肺癌疗效监测中的应用[J]. 检验医学, 2022, 37(1): 56-59.

胃癌患者外周血高迁移率族蛋白B-1水平的检测及临床意义

Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics